General Information
Pulmonary Arteriovenous Malformations
The Nose and Hereditary Haemorrhagic Telangiectasia
Pregnancy and Hereditary Haemorrhagic Telangiectasia
Telangiectasia Self Help Group Newsletter NO-16


TSHG Newsletter No 17 Part One of Two
TSHG Newsletter No 17 Part Two of Two
How to increase Iron in your diet
Dental Hygiene Infomrtaion
NHS Choices HHT Link


The Telangiectasia Self Help Group was founded in 1985 to maintain a register of sufferers and to put affected families in touch with one another.


The group was initially funded by a donation from the Thames/LWT Telethon Trust. A newsletter is sent to all members on an occasional basis informing them of the developments in the treatments of this disease.

Hereditary Haemorrhagic Telangiectasia
( HHT ) also known as Osler-Weber-Rendu disease, was first described over 100 years ago. It is due to a faulty gene and is very variable causing some people considerable distress whilst others escape with much less severe problems. For many patients, nosebleeds are the main problem although bleeding from the lining of the stomach and intestines occurs in about 20% of cases.


For further information or if you wish to become a member please contact :

Mrs Diana Lawson
Telangiectasia Self Help Group
39 Sunny Croft
High Wycombe
HP13 5UQ

Tel : (+44) 01494 528047

or alternatively E-mail:

info at


The Telangiectasia Self Help Group is affiliated to the following Support Groups :




© 2019, The Telangiectasia Self Help Group



AVM Support UK provides patient friendly information and support to all those whose lives have been affected by the rare condition Arteriovenous Malformation


The Contact a Family website is for families who have a disabled child and those who work with them


The Genetic Interest Group (GIG) is a national alliance of organisations with a membership of over 130 charities which support children, families and individuals affected by genetic disorders / genetic diseases


The HHT Foundation's new brand, Cure HHT, deepens and renews our commitment to the HHT community. We have one mission that drives everything we do – to find a cure for HHT disease, a genetic blood vessel disorder that affects 1 in 5,000 people - 90% of whom are undiagnosed


A ground-breaking study is being launched in 2017 to investigate the use of a new treatment for the management of patients presenting to hospitial with uncontrolled nose bleeds (epistaxis). See linked PDF infomrtaion pack or contact the co-ordinating team on 01752 439830